

# Curriculum vitae Tore Skotland

## PERSONAL INFORMATION

Family name, First name: Skotland, Tore

Sex: Male

Nationality: Norwegian

URL for personal web site: <https://www.ous-research.no/skotland/>

## EDUCATION

- 1980 Dr. philos. (Ph.D.; Biochemistry), University of Bergen, 1980. Dissertation: "Studies on dopamine  $\beta$ -monooxygenase from bovine adrenal medulla".
- 1974 M. Sci. (Cand. real; Biochemistry), University of Tromsø.
- 1972 B.Sci. (Chemistry, physics, matematics), University of Oslo.

## CURRENT AND PREVIOUS POSITIONS

- 2009- Senior Scientist, Centre for Cancer Biomedicine (Centre of Excellence), Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital.
- 1983-2009 Pharmaceutical R&D with focus on ADME (Adsorption, Distribution, Metabolism and Excretion) of contrast agents. Nycomed 1983-1997; Amersham 1997-2003; GE Healthcare 2003-2009 (Nycomed bought by Amersham in 1997 and Amersham bought by GE in 2003).
- 1983-1985: Senior researcher/project leader
- 1985-2003: Heading ADME/biochemistry work with all types of contrast agents
- 2003-2009: Special Scientific Advisor (Biochemistry/Metabolism/Bioanalysis)
- 1974-1983 Research assistant, researcher, assistant professor at The Biochemical Institute, University of Bergen.

## MANAGEMENT EXPERIENCE FROM PHARMACEUTICAL R&D

Being responsible for scientific and non-scientific issues for all employees in the department for 19 years (department size 7-32 persons; reorganizations in average every 2-3 year). Member of the company steering group for GLP (Good Laboratory Practice) for 15 years.

## SCIENTIFIC AND REGULATORY EXPERIENCE WITH ADME

I have been involved in the process of getting 5 intravenously injected contrast agents for medical use approved for marketing (*Visipaque*, *Infoson*, *Omniscan*, *Teslascan* and *Sonazoid*) and another 5 products into clinical trials (*iron oxide particles*, *liposomes*, two targeting peptides for nuclear medicine, hyperpolarized  $^{13}\text{C}$ -pyruvate for MRI). Four of these products are particle-based (written in italics). These include gas-filled particles for ultrasound imaging (gas stabilized with a shell of albumin or phospholipids), iron oxide particles for MRI and liposomes for CT. I am the first or last author on publications related to all these 10 products, thus demonstrating a very special competence in ADME. For several of these products I have been involved all the way from early exploratory

research to regulatory submission, launch and post marketing studies. This includes meetings/discussions with regulatory authorities in Europe, US and Japan.

### **INTERNATIONAL COLLABORATION**

I have a long experience in collaborating with many researchers both nationally and internationally. This includes scientists working in the world-wide organization of Nycomed, Amersham and GE Healthcare with R&D sites in Oslo, UK, USA, Germany and India. It also includes collaboration with people involved in strategic planning, quality aspects, regulatory approvals, and marketing in a company, which at that time had approximately 5500 employees working with contrast agents world-wide. Furthermore, this includes collaboration and discussions with people in Daichi Sankyo, a large pharmaceutical company licensing our products in Japan. As a world leading company in the field of contrast agents we frequently had discussions with leading scientists working at universities and hospitals world-wide

### **REVIEWING**

I have been a referee for several of the main journals in in bioanalysis, metabolism, biochemistry, nanoscience and radiology for many years.

### **PUBLICATIONS**

I have a total of 137 publications; H-index 40 (August 28<sup>th</sup> 2021).

See list at: <https://www.ous-research.no/skotland/>